Mary Wilson
Well-known member
November 26, 2021 at 3:31 PM EST
Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant
Company announcing a new variant-specific vaccine candidate against Omicron (mRNA-1273.529)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.
The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity.
... The Company is working rapidly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks.
https://investors.modernatx.com/new...es-strategy-address-omicron-b11529-sars-cov-2
Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant
Company announcing a new variant-specific vaccine candidate against Omicron (mRNA-1273.529)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.
The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity.
... The Company is working rapidly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks.
https://investors.modernatx.com/new...es-strategy-address-omicron-b11529-sars-cov-2